Hemophilia A Candidate SHP656 Fails to Meet Once-Weekly Dosing Goal, Partners Announce

The Phase 1/2 trial looking at the Factor VIII protein SHP656 as a long-acting therapeutic to treat hemophilia A did not meet a pre-defined once-weekly dosing criterion, according to Xenetic Biosciences and Shire, which are jointly developing the drug. The study demonstrated SHP656’s efficacy and pharmacokinetic data (the drug’s behavior once…

Why Hemophilia Is Called ‘A Royal Disease’

Hemophilia is a rare blood condition where people do not have the clotting factor which enables their blood to clot when bleeding. It’s an inherited disease that’s usually passed from mother to son. It’s also a disease that’s been prevalent in European royal families. MORE: A brief history of hemophilia…